Clinical ReportsAssociation between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancerRoviello, Giandomenicoa; Conca, Raffaelea; D’Angelo, Albertob; Multari, Andrea Giovannic; Paganini, Giovannid; Chiriacò, Giorgioe; Petrioli, Robertof; Corona, Silvia Paolag; Rosellini, Pietrof; Aieta, MicheleaAuthor Information aDivision of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero, Vulture (PZ), Italy bDepartment of Biology and Biochemistry, University of Bath, Bath, UK cUnit of Medical Oncology, Department of Oncology, Ospedale San Donato, Arezzo dUnit of general medicine, Azienda Ospedaliera ‘C. Poma’ Presidio ospedaliero di Pieve di Coriano, ASST Mantova eMedical Oncology Unit, Department of Oncology, ASST del Garda, Desenzano del Garda (BS) fDepartment of Medicine, Surgery and Neurosciences, Medical Oncology Unit, University of Siena, Siena gDepartment of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy Received 21 November 2019 Revised form accepted 24 December 2019 Correspondence to Giandomenico Roviello, MD, Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, via Padre Pio 1, 85028 Rionero, Vulture (PZ), Italy, Tel: +0577 586139; fax: +0557 948394; e-mail: firstname.lastname@example.org Anti-Cancer Drugs: July 2020 - Volume 31 - Issue 6 - p 632-636 doi: 10.1097/CAD.0000000000000905 Buy Metrics Abstract The aim of this study was to evaluate if the occurrence of neutropenia is correlated with response to ramucirumab plus paclitaxel for metastatic gastric cancer. This is a retrospective study of patients treated with ramucirumab plus paclitaxel. Fifty-three patients were evaluated. Among these, 10 patients (26.5%) developed grade ≥3 neutropenia. Patients with grade ≥3 neutropenia reported a progression-free survival of 6.6 months (95% confidence interval 3.3–8.4) and overall survival of 11 months (95% confidence interval 5.9–13.1) vs. 4.4 months (95% confidence interval 3.9–5.2) and 8.7 months (95% confidence interval 7.8–10.1) respectively in patients’ group with lower grade events. Our analysis seems to suggest that the occurrence of neutropenia predicts response to treatment with ramucirumab and paclitaxel. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.